Karyopharm Therapeutics Inc (OQ:KPTI)

Business Focus: Bio Therapeutic Drugs

Jul 05, 2019 05:31 am ET
Thinking about buying stock in Aurora Cannabis, Beyond Meat, Karyopharm Therapeutics, Northstar Realty, or Tyme Technologies?
NEW YORK, July 5, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BYND, KPTI, NRE, and TYME....
Jul 03, 2019 09:06 am ET
Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with...
Jun 28, 2019 12:37 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 55,500 shares of Karyopharm’s...
Jun 19, 2019 07:05 am ET
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported updated results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the Company’s first-in-class,...
Jun 14, 2019 03:00 am ET
 Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced three presentations highlighting new and updated data from the Phase 1b/2 STOMP (Selinexor and Backbone Treatments of Multiple Myeloma Patients)...
Jun 03, 2019 12:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 95,500 shares of Karyopharm’s...
May 28, 2019 03:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Jefferies 2019 Global Healthcare...
May 16, 2019 07:06 am ET
Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that five abstracts relating to selinexor, the Company’s first in class, oral SINE compound, will be presented at the upcoming European Hematology...
May 15, 2019 03:00 am ET
Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, congratulates its founder, President and Chief Scientific Officer, Sharon Shacham, PhD, MBA, for winning the esteemed New York Intellectual Property Law...
May 09, 2019 03:02 am ET
Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2019 and provided an overview of recent accomplishments and clinical development progress for its innovative...
May 08, 2019 03:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Bank of America Merrill Lynch Health Care...
May 02, 2019 03:00 am ET
Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2019 financial results on Thursday, May 9, 2019. Karyopharm's management team will host a conference call and...
May 01, 2019 12:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 89,500 shares of Karyopharm’s...
Apr 10, 2019 04:35 am ET
New Research Coverage Highlights BioMarin Pharmaceutical, EnLink Midstream, GCI Liberty, Vistra Energy, BioTime, and Karyopharm Therapeutics — Consolidated Revenues, Company Growth, and Expectations f
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), EnLink Midstream, LLC (NYSE:ENLC),...
Apr 01, 2019 12:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 38,000 shares of Karyopharm’s...
Mar 14, 2019 12:57 pm ET
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for selinexor. The NDA, which is currently under Priority Review by the FDA, is seeking accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is...
Feb 28, 2019 11:51 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that it has granted stock options to Michael P. Mason, the Company’s newly-appointed Senior Vice President, Chief Financial Officer and Treasurer,...
Feb 28, 2019 02:00 am ET
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and full year 2018 and provided a business update and an overview of recent accomplishments for selinexor,...
Feb 26, 2019 12:47 pm ET
Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss the New Drug Application (NDA) for...
Feb 26, 2019 07:31 am ET
Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that NASDAQ has halting trading of the Company’s common stock. The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee...
Feb 25, 2019 02:00 am ET
Karyopharm Strengthens Management Team with Appointment of Michael P. Mason as Chief Financial Officer
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Michael P. Mason as Senior Vice President, Chief Financial Officer and Treasurer. In this role, Mr. Mason will be responsible...
Feb 21, 2019 02:35 am ET
Research Report Identifies Johnson & Johnson, Schlumberger, Karyopharm Therapeutics, WYNDHAM DESTINATIONS, INC, ASGN, and Suburban Propane Partners with Renewed Outlook — Fundamental Analysis, Calcula
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Johnson & Johnson (NYSE:JNJ), Schlumberger Limited (NYSE:SLB), Karyopharm...
Feb 21, 2019 02:00 am ET
Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. Karyopharm's management team will host a...
Feb 07, 2019 02:00 am ET
Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the...
Feb 04, 2019 02:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 428,500 shares of...
Jan 08, 2019 07:20 am ET
Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for selinexor, the Company’s...
Jan 02, 2019 11:05 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 78,000 shares of Karyopharm’s...
Jan 02, 2019 02:00 am ET
Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7,...
Dec 04, 2018 02:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 180,500 shares of...
Dec 03, 2018 06:00 am ET
Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced presentations highlighting updated data from the Phase 2b STORM study evaluating selinexor, the Company’s first-in-class, oral Selective Inhibitor...
Dec 01, 2018 07:00 am ET
Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the Company’s...
Nov 13, 2018 03:10 am ET
Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Evelo Biosciences, Inc. (NASDAQ:EVLO), ADMA Biologics Inc (NASDAQ:ADMA),...
Nov 08, 2018 02:00 am ET
Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2018 and provided an overview of recent accomplishments for selinexor, its lead, novel, oral SINE compound,...
Nov 07, 2018 03:00 am ET
Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound...
Nov 07, 2018 02:00 am ET
Karyopharm to Present at the Jefferies 2018 London Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14,...
Nov 05, 2018 02:00 am ET
Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and Chief Scientific Officer and cofounder Michael G. Kauffman MD,...
Nov 02, 2018 03:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 127,500 shares of...
Nov 01, 2018 06:17 am ET
Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that ten abstracts have been selected for presentation, including three oral presentations, at the upcoming American Society of Hematology (ASH)...
Nov 01, 2018 03:00 am ET
Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2018 financial results on Thursday, November 8, 2018. Karyopharm's management team will host a conference call...
Oct 29, 2018 03:00 am ET
Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes”) pursuant to...
Oct 26, 2018 03:00 am ET
Karyopharm Therapeutics Announces Management Change
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Mike Falvey, Executive Vice President, Chief Financial Officer and Treasurer, intends  to leave the company to pursue other interests.   Mr....
Oct 11, 2018 03:00 am ET
Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “Notes”).  The Notes will be sold in a...
Oct 09, 2018 12:01 pm ET
Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2025 (the...
Oct 05, 2018 01:43 pm ET
U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) seeking accelerated...
Oct 01, 2018 03:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 108,900 shares of...
Sep 25, 2018 03:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:  The Cantor Fitzgerald Global...
Sep 20, 2018 12:05 pm ET
Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two oral presentations and one poster presentation highlighting previously reported clinical data relating to selinexor, the Company’s lead, oral...
Sep 13, 2018 03:20 pm ET
Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that updated clinical data from the Phase 2b STORM (Selinexor Treatment of Refractory Myeloma) study evaluating selinexor, the Company’s lead, oral...
Sep 04, 2018 12:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 62,500 shares of Karyopharm’s...
Sep 04, 2018 03:00 am ET
Karyopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Carsten Thiel, Ph.D., to its Board of Directors. Dr. Thiel is currently Chief Executive Officer of Abeona Therapeutics Inc., a...
Aug 29, 2018 03:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:  The Baird 2018 Global Healthcare...
Aug 28, 2018 02:22 pm ET
Karyopharm to Present Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma at the Society of Hematologic Oncology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical data from the Phase 2b STORM study evaluating the Company’s lead, oral Selective Inhibitor of Nuclear Export (SINE) compound...
Aug 17, 2018 03:45 am ET
Report: Developing Opportunities within FORTERRA INC, Baytex Energy, MAG Silver, Bojangles', Ciner Resources LP, and Karyopharm Therapeutics — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FORTERRA INC (NASDAQ:FRTA), Baytex Energy Corp (NYSE:BTE), MAG Silver...
Aug 07, 2018 03:00 am ET
Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2018 and provided an overview of recent accomplishments and clinical development plans for selinexor, its...
Aug 06, 2018 12:05 pm ET
Karyopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated...
Aug 03, 2018 03:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 196,500 shares of Karyopharm’s...
Aug 02, 2018 03:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:  The Canaccord Genuity 38th Annual...
Jul 31, 2018 03:00 am ET
Karyopharm to Report Second Quarter 2018 Financial Results on August 7, 2018
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2018 financial results on Tuesday, August 7, 2018. Karyopharm's management team will host a conference call and...
Jul 25, 2018 12:05 pm ET
Karyopharm Appoints Ian Karp as Vice President, Investor and Public Relations
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Ian Karp as Vice President, Investor and Public Relations.  In this role, Mr. Karp will lead all of the Company’s corporate...
Jul 18, 2018 03:00 am ET
Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...
Jul 02, 2018 03:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 146,500 shares of Karyopharm’s...
Jun 25, 2018 03:00 am ET
Karyopharm Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Anand Varadan as Executive Vice President, Chief Commercial Officer. In this role, Mr. Varadan will lead Karyopharm’s commercial...
Jun 15, 2018 03:00 am ET
Karyopharm Presents Updated Selinexor Phase 1b/2 STOMP Myeloma Data from Multiple Combinations at the European Hematology Association 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three posters highlighting clinical data from the ongoing Phase 1b/2 STOMP study in patients with multiple myeloma (MM) will be presented at...
Jun 01, 2018 12:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 77,000 shares of Karyopharm’s...
Jun 01, 2018 03:00 am ET
Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four posters will be presented at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting taking place June 1-5, 2018 in...
May 31, 2018 03:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:  The Jefferies 2018...
May 30, 2018 03:40 am ET
Report: Exploring Fundamental Drivers Behind PDC Energy, Black Stone Minerals, BJ's Restaurants, Karyopharm Therapeutics, SBA Communications, and BLACKLINE INC — New Horizons, Emerging Trends, and Upc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDC Energy, Inc. (NASDAQ:PDCE), Black Stone Minerals, L.P. (NYSE:BSM),...
May 24, 2018 03:00 am ET
Karyopharm and Antengene Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) (Karyopharm) and Antengene Corporation (Antengene), today announced their entry into an exclusive license agreement for the development and commercialization of four of Karyopharm’s novel, oral drug...
May 17, 2018 06:12 am ET
Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three posters highlighting clinical data from the ongoing Phase 1b/2 STOMP study will be presented at the upcoming European Hematology...
May 16, 2018 01:31 pm ET
Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four posters will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2018 Annual Meeting taking place June 1-5, 2018 in...
May 10, 2018 03:00 am ET
Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2018 and provided an overview of recent accomplishments and clinical development plans for selinexor, its...
May 07, 2018 12:05 pm ET
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ option to purchase...
May 04, 2018 03:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 103,500 shares of Karyopharm’s...
May 03, 2018 03:00 am ET
Karyopharm to Report First Quarter 2018 Financial Results on May 10, 2018
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2018 financial results on Thursday, May 10, 2018. Karyopharm's management team will host a conference call and...
May 02, 2018 05:46 pm ET
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of its previously announced registered underwritten public offering of 9,152,543 shares of its common stock at a price to the public of...
May 01, 2018 12:33 pm ET
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
NEWTON, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the commencement of a registered underwritten public offering of $125 million in shares of its common stock. In addition, Karyopharm...
Apr 30, 2018 12:05 pm ET
Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma
- Oral Selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory Myeloma -
Apr 10, 2018 03:00 am ET
Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
NEWTON, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead, oral Selective Inhibitor...
Apr 05, 2018 03:45 am ET
Report: Developing Opportunities within Insulet, Karyopharm Therapeutics, Playa Hotels & Resorts N.V, Cision Ltd., Freightcar America, and COUPA SOFTWARE — Future Expectations, Projections Moving into
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Insulet Corporation (NASDAQ:PODD), Karyopharm Therapeutics Inc....
Apr 02, 2018 03:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 321,500 shares of...
Mar 19, 2018 12:05 pm ET
Karyopharm to Present Preclinical Data at the American Association for Cancer Research 2018 Annual Meeting
Five Posters Highlighting Selinexor Data, Including in Combinations with Zejula® (niraparib) in Ovarian Cancer and Velcade® (bortezomib) in Neuroblastoma
Mar 15, 2018 03:00 am ET
Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
− Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Myeloma Remains on Track; Top-Line Data Expected end of April 2018 –− Company Executes Two High-Value Strategic Transactions Providing Substantial Validation for Its Lead Assets and XPO1 Inhibition –
Mar 08, 2018 02:00 am ET
Karyopharm to Report Fourth Quarter and Year End 2017 Financial Results on March 15, 2018
Conference Call Scheduled for Thursday, March 15, 2018 at 8:30 a.m. ET
Mar 01, 2018 11:05 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 20,300 shares of...
Feb 09, 2018 03:00 am ET
Analysis: Positioning to Benefit within AECOM, Wolverine World Wide, Dorchester Minerals, Bruker, Fred's, and Karyopharm Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AECOM (NYSE:ACM), Wolverine World Wide, Inc....
Feb 07, 2018 02:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
NEWTON, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will participate in fireside chat discussions at the following upcoming investor conferences being held...
Feb 01, 2018 11:05 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 159,000 shares of...
Jan 31, 2018 02:00 am ET
Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy
NORWALK, Conn. and NEWTON, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research Foundation (MMRF), the world’s number one private funder of multiple myeloma research, and Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today highlighted...
Jan 25, 2018 01:30 am ET
Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions
− Biogen Brings Expertise in Development and Commercialization of Products for Neurological and Neurodegenerative Diseases –
Jan 03, 2018 02:00 am ET
Karyopharm Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday,...
Dec 10, 2017 01:05 pm ET
Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting
− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma –
Dec 10, 2017 01:00 pm ET
Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting
− Data Provide Further Evidence of Tolerability with Robust Anti-Myeloma Activity When Selinexor is Combined with Velcade, Pomalyst, Revlimid or Darzalex –
Nov 13, 2017 02:00 am ET
Karyopharm Therapeutics to Present at the Jefferies 2017 London Healthcare Conference
NEWTON, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conference on Thursday, November...
Nov 03, 2017 03:00 am ET
Karyopharm Therapeutics to Participate in the Credit Suisse 26th Annual Healthcare Conference
NEWTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Credit Suisse 26th Annual Healthcare Conference on Wednesday,...
Nov 02, 2017 03:00 am ET
Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
− Company Completes Exclusive Licensing Transaction Valued at Up To $193 Million Plus Royalties with Ono Pharmaceutical Co. Ltd. for Selinexor and KPT-8602 In Japan and Certain Other Countries in Asia –
Nov 01, 2017 05:27 am ET
Aug 30, 2017 02:49 pm ET
Karyopharm Announces the Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting, taking place September 8-12, 2017 in Madrid, Spain.  One poster will describe Phase 1 data from an ongoing investigator-sponsored trial (IST) evaluating the safety and tolerability of the Company’s lead product candidate, selinexor (KPT-330), an oral Selective Inhibitor of Nuclear Export / SINE™ compound, in combination with paclitaxel and ...
Aug 08, 2017 03:00 am ET
Jun 07, 2017 12:05 pm ET
Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
NEWTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in its pivotal Phase 3 study, named the BOSTON (Bortezomib, Selinexor and dexamethasone) study, which will evaluate selinexor (KPT-330), the Company’s lead, novel, oral Selective Inhibitor of Nuclear Export (SINE™) compound, in combination with Velcade® (bortezomib) and dexamethasone (SVd), in patients with relapsed or refractory multiple myeloma (MM)....
May 03, 2017 12:05 pm ET
Karyopharm and Anivive Lifesciences Sign Exclusive Global License Agreement for Verdinexor for Animal Health Applications
− Anivive Aims to Develop and Commercialize Verdinexor for the Treatment of Cancer in Companion Animals –...
Apr 24, 2017 12:01 pm ET
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
NEWTON, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it is commencing a registered underwritten public offering of $40 million in shares of its common stock. In addition, Karyopharm has granted the underwriter a 30-day option to purchase up to $6 million in shares of its common stock....
Apr 03, 2017 12:05 pm ET
Karyopharm Announces Management Change
NEWTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin Renz, Executive Vice President, Chief Financial Officer and Treasurer, has stepped down in order to pursue other opportunities, effective today.  Mr. Renz will continue to serve the Company in an advisory capacity in order to ensure a smooth transition....
Mar 31, 2017 12:25 pm ET
Karyopharm to Present Selinexor Phase 2b SADAL Data at the American Association for Cancer Research Annual Meeting 2017
Abstract Published Today Highlighting Interim Phase 2b SADAL Results in Patients with Relapsed or Refractory DLBCL...
Mar 10, 2017 02:55 pm ET
Karyopharm Announces Partial Clinical Hold to Pause Enrollment in Selinexor Trials
All Currently Enrolled Patients with Stable Disease or Better Can Continue Receiving Selinexor...
Mar 02, 2017 11:05 am ET
Karyopharm Announces Results from Interim Analysis of Phase 2 SOPRA Study Evaluating Selinexor in Relapsed/Refractory Acute Myeloid Leukemia
Study Will Not Reach Statistically Significant Improvement in Primary Endpoint of Overall Survival in Patients who are Unfit for Chemotherapy and/or Transplantation; Patients Deriving Benefit to Remain on Study...
Mar 01, 2017 01:08 pm ET
Karyopharm Announces the Presentation of New Data at the 2017 American Association for Cancer Research Annual Meeting
Late-Breaking Presentation Highlighting Interim Phase 2b Selinexor Data in Patients with Relapsed or Refractory DLBCL (SADAL Study)...
Jan 31, 2017 02:30 am ET
Karyopharm to Participate in Upcoming Investor Conferences
NEWTON, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will participate in the following upcoming investor conferences:...
Dec 15, 2016 02:30 am ET
Karyopharm and Collaborators Awarded Grant for ALS Research
 - Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS -...
Dec 05, 2016 12:45 pm ET
Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting
- STOMP Data Continues to Demonstrate High Response Rates in Patients with Heavily Pretreated Multiple Myeloma When Selinexor Is Combined with Bortezomib and Pomalidomide -...
Dec 04, 2016 02:30 pm ET
Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting
- Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -...
Dec 04, 2016 07:30 am ET
Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting
- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia -...
Nov 03, 2016 06:00 am ET
Nov 03, 2016 05:43 am ET
Karyopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting
- Diverse Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -...
Nov 02, 2016 03:30 am ET
Karyopharm to Ring the Nasdaq Stock Market Closing Bell
NEWTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and Chief Scientific Officer and cofounder Michael G. Kauffman MD, PhD, Chief Executive Officer, will ring the Nasdaq Closing Bell at 4:00 p.m. ET on Friday, November 4, 2016 at the Nasdaq MarketSite in New York City to commemorate the eighth anniversary of the Company’s founding....
Oct 31, 2016 03:30 am ET
Karyopharm to Report Third Quarter 2016 Financial Results on November 7, 2016
NEWTON, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2016 financial results and provide a company update on Monday, November 7, 2016. Karyopharm's management team will host a conference call and audio webcast at 5:00 p.m. ET on Monday, November 7, 2016 to discuss the financial results and recent business developments....
Oct 11, 2016 03:30 am ET
Karyopharm to Present at the 15th Annual BIO Investor Forum
NEWTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Executive Vice President, Chief Financial Officer, and Treasurer, will present at the 15th Annual BIO Investor Forum on Tuesday, October 18, 2016 at 11:00 a.m. PT. The conference will be held at the Westin St. Francis in San Francisco....
Oct 05, 2016 02:18 am ET
Karyopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting
- Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers -...
Sep 29, 2016 03:30 am ET
Karyopharm Publishes Preclinical Data in Nature Demonstrating Selinexor’s Potential in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
- Nuclear Transport Machinery Identified as a Necessary and Universal Driver of KRAS-mutant Cell Survival - ...
Sep 28, 2016 03:30 am ET
Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication
- XPO1 Inhibition Significantly Reduced Tumor Burden in Platinum Sensitive and Resistant Ovarian Cancer Models-...
Sep 12, 2016 03:30 am ET
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD, FCAP, as Senior Vice President, Clinical Development. Dr. Gardner will be responsible for clinical development planning and strategy, including building and leading clinical teams to achieve the Company’s long-term strategic objectives, and will report to Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm....
Aug 30, 2016 08:14 am ET
Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans
NEWTON, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced it will provide an overview of top-line results from its Phase 2b STORM study and the planned development path for selinexor (KPT-330) in multiple myeloma (MM) on Tuesday, September 6, 2016, followed by a conference call on Tuesday, September 6, 2016 at 8:30 a.m., Eastern time.  To access the conference call, please dial (855) 437-4406 (US) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference...
Aug 04, 2016 03:30 am ET
Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma...
Aug 03, 2016 03:30 am ET
Karyopharm to Present at Upcoming Investor Conferences
NEWTON, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will present at the following upcoming investor conferences:...
Jul 28, 2016 04:00 am ET
Karyopharm to Report Second Quarter 2016 Financial Results on August 4, 2016
NEWTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016 financial results and provide a company update on Thursday, August 4, 2016. Karyopharm’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, August 4, 2016 to discuss the financial results and recent business developments....
Jul 27, 2016 12:05 pm ET
Jul 27, 2016 03:30 am ET
Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published in Journal of Clinical Oncology
Data Provide Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase 2 Dose...
Jul 06, 2016 03:30 am ET
Karyopharm to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
NEWTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 8:30 a.m. ET. The conference will be held at Le Parker Meridien New York....
Jun 22, 2016 03:30 am ET
Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
NEWTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1 clinical trial evaluating KPT-9274, an oral, first-in-class, dual-acting p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, in patients with advanced solid malignancies (including sarcoma, colon and lung cancer) or non-Hodgkin's lymphoma (NHL) whose disease has relapsed after standard therapy(s) (NCT02702492)....
Jun 16, 2016 03:30 am ET
Karyopharm Outlines Key Selinexor Clinical Development Achievements
- Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma -...
Jun 15, 2016 03:30 am ET
Karyopharm to Present at the 2016 JMP Securities Life Science Conference
NEWTON, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 2:00 p.m. E.T. The conference will be held at the St. Regis Hotel in New York....
Jun 10, 2016 03:30 am ET
Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma -...
Jun 01, 2016 04:00 am ET
Karyopharm to Present at the Jefferies 2016 Healthcare Conference
NEWTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, is scheduled to present at the upcoming Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 3:00 p.m. ET....
May 19, 2016 03:30 am ET
Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
NEWTON, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary activity of selinexor (KPT-330) and dexamethasone in combination with bortezomib (Velcade®), pomalidomide (Pomalyst®), or lenalidomide (Revlimid®) for the treatment of relapsed/refractory multiple myeloma (MM) (the STOMP study) has been accepted for presentation at the 21st Congress of the European Hematology Association (EHA) held June 9-12, 2016 in Copenhagen, Denmark. The abstract describes preliminar...
May 18, 2016 01:40 pm ET
Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
NEWTON, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor (KPT-330), the Company’s lead product candidate selinexor in development for hematological malignancies and solid tumors, have been selected for two poster presentations and one poster discussion at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. Updated and detailed results from these studies will be presented at the conference. The abstracts, whic...
May 09, 2016 03:30 am ET
Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma...
May 02, 2016 04:00 am ET
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016
NEWTON, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, May 9, 2016 to discuss the financial results and recent business developments....
Apr 06, 2016 07:00 am ET
Karyopharm Taps TransPerfect as eTMF and Functional TMF Provider
NEW YORK, April 6, 2016 /PRNewswire/ -- TransPerfect, a leading provider of global development and commercialization solutions to the life sciences industry, today announced that Karyopharm Therapeutics has implemented Trial Interactive as its electronic Trial Master File (eTMF)....